Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		10802143	
	Filing Date		2004-03-16	
	First Named Inventor	T. TA	KEYAMA	
	Art Unit		1756	
	Examiner Name	Martin	J. ANGEBRANNDT	
Attorney Docket Number		er	KON-1860	

				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4963471		1990-10-16	E. I. DU PON AND COMPA	T de NEMOURS NY			
	2	6483611		2002-11-19	DENSO COR	PORATION			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1								
If you wisl	h to a	dd additional U.S. Pub	lished Ap	plication citation	n information	please click the Ad	d buttor	Add	
				FOREIGN PA	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	8220975	JP		1996-08-30	TOYO INK MFG C	OLTD	with English Abstract	
	2	03014178	wo		2003-02-20	INPHASE TECHNOLOGIES,	INC.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10802143		
Filing Date		2004-03-16		
First Named Inventor	T. TAKEYAMA			
Art Unit		1756		
Examiner Name Martin		J. ANGEBRANNDT		
Attorney Docket Number		KON-1860		

Date Considered

	3	0368629	EP		1990-05-16	THE MEAD CORPORATION			
	4	0339841	EP		1989-11-02	THE MEAD CORPORATION			
	5	2002123949	JP		2002-04-26	OPTWARE:KK	with English Abstract		
	6	9957719	wo		1999-11-11	OPTILINK AB			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Ţ5		
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE

See Kink Codes of USPTO Patent Documents at invent USPTO, COV or MIPP 901.04. * Enter office that issued the document, by the No-letter code (WIPO Standard ST.3.) * For Laplanese patent for counters, the indication of the year of the region or the Empirer small precise the sensit number of the patent consumer of the Counter of the patent consumers of the Counter o

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10802143	
Filing Date		2004-03-16	
First Named Inventor	T. TA	KEYAMA	
Art Unit		1756	
Examiner Name Martin		J. ANGEBRANNDT	
Attorney Docket Number		KON-1860	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to father of information disclosure statement was known to any individual designated in 37 CFR 1/50(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/37(4).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	of the agradate.								
	Signature	/DCL/	Date (YYYY-MM-DD)	2007-03-20					
	Name/Print	Donald C. Lucas	Registration Number	31275					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 122 and 3T CFR 1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S Petent and Trademark Office, U.S Operatment of Commence, P. 0. Dax 1450, Alexandris, V.3.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.